Trials / Completed
CompletedNCT01190475
BGS649 Monotherapy in Moderate to Severe Endometriosis Patients
A Randomized, Double-blind, Double-dummy, Placebo-controlled Study of Oral BGS649 Monotherapy Assessing Safety and Tolerability in Patients With Moderate to Severe Endometriosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Mereo BioPharma · Industry
- Sex
- Female
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety and tolerability of BGS649 in women with moderate to severe endometriosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Active treatment with a high dose of BGS649 | |
| DRUG | Active treatment with a low dose of BGS649 | |
| DRUG | Placebo treatment to blind study |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2010-08-27
- Last updated
- 2020-10-27
- Results posted
- 2017-12-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01190475. Inclusion in this directory is not an endorsement.